Invasive pulmonary aspergillosis and pulmonary cryptococcosis really coexist in immunocompromised host.
Fungal infections develop slowly in immunocompetent patients and rarely a severe disease, however, they progress rapidly and usually prove fatal in immunocompromised patients. Early diagnosis and treatment of fungal infections is essential to survival of immunocompromised patients. We report a 33-year-old woman with systemic lupus erythematosus undergoing immunotherapy infected with combined invasive pulmonary aspergillosis and pulmonary cryptococcosis diagnosed by video-assisted thoracic surgery lung biopsy and she was successfully treated as a result of early diagnosis and treatment.
Lin
Chih-Ming
CM
Division of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, 199 Tun-Hwa North Road, Taipei 105, Taiwan. lin789@adm.cgmh.org.tw
Tsai
Ying-Huang
YH
Huang
Chung-Chi
CC
Lee
Cheng-Huei
CH
Chiang
Ping-Cherng
PC
Huang
Shiu-Feng
SF
Liu
Hui-Ping
HP
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications* / Q000188:drug therapy; D003453:Cryptococcosis / Q000150:complications* / Q000188:drug therapy; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000150:complications* / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D000666:Amphotericin B; D015725:Fluconazole